ISSCR: grave omission of age limit for embryo research
By Josephine Johnston, Françoise Baylis & Henry T. Greely,
Nature
| 06. 22. 2021
We are researchers with differing views on the ethics of stem-cell and embryo research who nonetheless share deep concerns about the latest guidelines from the International Society for Stem Cell Research (ISSCR; see R. Lovell-Badge Nature 593, 479; 2021).
The 2016 ISSCR guidelines ruled out experiments on human embryos beyond 14 days, citing broad international consensus that these lacked “a compelling scientific rationale, raise substantial ethical concerns, and/or are illegal in many jurisdictions” (see go.nature.com/3cqc4bw). The latest guidelines drop this prohibition (see go.nature.com/3gfkkw8) and do not propose any alternative.
At some point, the developing human embryo reaches a stage at which it should not be used for research. There is disagreement about when that happens, but scientists need to acknowledge that it does, and reassure the public that they accept limits. The latest guidelines do not prohibit the development or research use of ex vivo embryos at any stage.
Defining and defending a new limit, and possible constraints within it, will be hard. This was the case for the 14-day cut-off, selected some 40 years ago. But setting no limit is a grave omission.
Related Articles
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Dan Falk, Nautilus | 08.20.2026
The pseudoscience of eugenics, founded on the mistaken notion that nature envisions some “right” combination of genes, and that selective breeding can improve the human race, is making a comeback. While the heyday of eugenics was a century ago, the...
By Emily Packard Dawson and Lainie Friedman Ross, MedPage Today | 08.18.2026
Few things evoke a greater sense of desperation than a parent seeking an experimental treatment for their child. That desperation can make even extraordinary risks seem worth taking. This dynamic has come into stark relief after Mei, a 6-year-old girl...
By Ryan Cross, Endpoints News | 08.20.2026
China’s cheap, fast and quiet system for testing cutting-edge medicines is facing scrutiny after the deaths of three people in investigator-initiated trials.
The studies, also known as IITs, allow experimental cell and gene therapies to be tested without oversight from...